US-Egypt Cooperative Research: Preparation of Haemophilus Influenza Type B/Tetanus Toxoid Conjugate Vaccine

描述：该奖项是为了支持玛丽博士的合作项目。Mikhail，高级研究员，肠道微生物学，在海军医学研究单位-3（NAMU 3）在开罗，埃及和Alaa Eldin Shehata Aly，高级化学家，生物医学研究中心，埃及生物制品和疫苗组织（VACSERA），在开罗，埃及。 这两个合作者计划合成一种新的疫苗，用于保护婴儿免受B型流感嗜血杆菌（HiB）疾病的侵害。 将制备并纯化Hib的多糖，然后解聚并单端偶联至载体蛋白（破伤风类毒素的150 KD级分）。 这将提高其免疫原性，特别是在婴儿中，并导致更好的保护和更长的免疫应答持续时间，具有T细胞依赖性特征。 所产生的缀合物将具有高半抗原负荷，因此将在致敏婴儿中更有活性，并且在成人中更有活性。 将在实验室动物中检测结合物的免疫应答改善。 适用范围：该项目将涉及两个实验室，它们具有在重要的工业和卫生研究领域进行研究的互补能力。 部分研究工作将在VACSERA进行，包括Hib CPS的纯化和偶联物的制备。 TT分馏、Hib CPS解聚、高碘酸盐氧化和化学偶联的步骤将由VACSERA和NAMU 3团队联合审查。 结合物的化学检测也将联合进行。 动物免疫将在NAMRU 3进行。 Mikhail博士是生物化学和动物临床试验方面的专家。 埃及研究人员是多糖蛋白结合疫苗制备领域的专家，在细菌荚膜多糖的纯化和检测方面有经验。 该提案符合INT支持美国与外国在互利领域合作的目标。 该项目是国家卫生研究所和埃及政府举办的生物技术讲习班的结果。 国家卫生研究所参与了对该项目的评估，并建议给予支持。 该项目得到美国-埃及联合基金方案的支持，该方案由美国国务院管理，向两国的科学家和工程师提供赠款，以开展合作活动。

Description: This award is for support of a cooperative project by Dr. Mary M. Mikhail, Senior Investigator, Enteric Microbiology, at the Naval Medical Research Unit -3 (NAMRU3) in Cairo, Egypt, and Alaa Eldin Shehata Aly, Senior Chemist, Biomedical Research Center, Egyptian Organization for Biological Products and Vaccines (VACSERA), in Cairo, Egypt. The two collaborators plan to synthesize a new vaccine for the protection of infants against Haemophilus influenza type b (Hib) diseases. The polysaccharide of Hib will be prepared and purified then depolymerized and uniterminally coupled to a carrier protein (150KD fraction of tetanus toxoid). This will improve its immunogenecity specially in infants and lead to a better protection and longer duration of immune response with T-cell dependent characters. The conjugate produced will be of high hapten load so will be more active in priming infants, and more active in adults. The improvement of the immune response of the conjugate will be tested in laboratory animals. Scope: This project will involve two laboratories with complementary capabilities to conduct research in an important industrial and health research field. Part of the research work will be conducted at VACSERA, including the purification of Hib CPS and the preparation of the conjugate. The steps of TT fractionation, Hib CPS depolymerization, periodate oxidation and chemical coupling will be jointly reviewed by VACSERA and the NAMRU3 teams. The chemical testing of the conjugate also will be carried out jointly. The animal immunization will be done at NAMRU3. Dr. Mikhail is an expert in biological chemistry and animal clinical testing. The Egyptian researcher is an expert in the field of polysaccharide protein conjugated vaccine preparation, and has experience in purification and testing of bacterial capsular polysaccharides. This proposal meets the INT objective of supporting US-foreign collaboration in areas of mutual benefit. The project was generated as a result of a workshop on biotechnology organized by the National Institutes of Health (NIH) and the Egyptian Government. NIH was involved in the evaluation of the project and in recommending its support. This project is being supported under the US-Egypt Joint Fund Program, administered by the US Department of State, which provides grants to scientists and engineers in both countries to carry out cooperative activities.